Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

We examined a novel farnesoid X receptor agonist, EDP‐305, for its antifibrotic effect in bile duct ligation (BDL) and choline‐deficient, L‐amino acid‐defined, high‐fat diet (CDAHFD) models of hepatic injury. We used molecular magnetic resonance imaging with the type 1 collagen‐binding probe EP‐3533...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Hepatol Commun
Auteurs principaux: Erstad, Derek J., Farrar, Christian T., Ghoshal, Sarani, Masia, Ricard, Ferreira, Diego S., Chen, Yin‐Ching Iris, Choi, Ji‐Kyung, Wei, Lan, Waghorn, Phillip A., Rotile, Nicholas J., Tu, Chuantao, Graham‐O'Regan, Katherine A., Sojoodi, Mozhdeh, Li, Shen, Li, Yang, Wang, Guogiang, Corey, Kathleen E., Or, Yat Sun, Jiang, Lijuan, Tanabe, Kenneth K., Caravan, Peter, Fuchs, Bryan C.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6049071/
https://ncbi.nlm.nih.gov/pubmed/30027140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1193
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires